Abbott Biaxin XL
"Some time in the third quarter, in advance of this year's flu season, we expect to hear from the FDA on our XL filing for community-acquired pneumonia," Abbott's Babington reports. Abbott filed for the new Biaxin XL indication in September 2000. The extended-release formulation of Abbott's macrolide antibiotic clarithromycin has "conversion tracking at more than 45% for the year"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth